New Bacterial Vaccines

In recent years, with the advent of recombinant DNA technology and major breakthroughs in molecular biology and immunology, a new dimension has been given to the design of vaccine strains. Powerful genetic and immunological technigues allow the production of new vaccines. In this article Haemophilus influenzae, acellular pertussis, typhoid, pneumococcal and meningococcal polysaccharide vaccines have been reviewed under the sight of current literature

AMONYUM BORHİDRÜRÜN ZEOLİTLER ÜZERİNDE YENİDEN HİDROJENASYONU

AMONYUM BORHİDRÜRÜN ZEOLİTLER ÜZERİNDE YENİDEN HİDROJENASYON

Pneumococcal Meningitis in Children: Evaluation of 46 Cases

A retrospective study was performed to review the clinical features, laboratory findings and the outcome of 46 children with pneumococcal meningitis hospitalized in a 10-year period. The median age of the cases was 3 years (range 1.5 months-11 years). Forty-eight percent of the cases were younger than two years of age. Nine out of the 46 children (19.5%) had underlying conditions. All of the strains isolated were susceptible to penicillin. Thirty-six patients were treated with crystallized penicillin, 8 patients with ceftriaxone and 2 patients with vancomycin plus ceftriaxone. A mortality rate of 10.8% was observed. At discharge, 13 survivors (28%) had neurologic sequelae as developmental delay, hearing loss, spasticity and/or paresis, and seizure disorder. The importance of early diagnosis and treatment of pneumococcal meningitis was emphasized